樂普醫療(300003.SZ)半年度扣非淨利潤升21.2%至11.14億元
格隆匯 8 月 27日丨樂普醫療(300003.SZ)發佈2020年半年度報告,實現營業收入423,783.92萬元,同比增長8.08%;實現營業利潤137,540.93萬元,同比增長3.50%;實現利潤總額139,203.02萬元,同比增長0.64%;實現淨利潤118,398.27萬元,同比增長2.15%;實現歸屬於上市公司股東的淨利潤114,034.66萬元,同比降低1.30%;扣除非經常損益後歸屬於上市公司股東的淨利潤111,449.64萬元,同比增長21.20%;實現經營活動產生的現金流量淨額113,706.37萬元,同比增長61.72%;加權平均淨資產收益率為14.13%,較上年同期降低2.80個百分點。
醫療器械板塊是公司業務規模最大的部分。報告期內,該板塊實現營業收入225,537.93萬元,同比增長29.16%,繼續保持了較快的增長態勢。公司自產器械產品包括泛心血管核心器械和非心血管器械。報告期內,自產器械產品實現營業收入207,740.69萬元,同比增長36.84%。
報告期末,公司對體外診斷業務由收購導致的部分技術知識產權進行審慎評估計提減值準備5,630.77萬元,對歸屬於上市公司股東的淨利潤的影響為5,020.95萬元。
報告期內,非經常性損益對公司歸屬於上市公司股東的淨利潤影響金額為2,585.02萬元,主要是公司收到的政府補助;上年同期主要由君實生物相關收益形成的非經常性損益23,581.08萬元,同比顯著降低。報告期內扣除非經常損益後歸屬於上市公司股東的淨利潤較上年同期增長21.20%。
若剔除上述計提特定減值以及非經常性業務的影響,歸屬於上市公司股東的淨利潤為116,470.59萬元,較上年同期口徑的91,956.58萬元增長26.66%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.